Evidence map›Paper›PMID 42045562›Full record

ReviewNature protocols2026

Preparation of C4'-modified nucleoside analogs.

Thirupathi Nuligonda, Gautam Kumar, Jason W Wang, Lara K Mahal, Michael W Meanwell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Thirupathi NuligondaDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Gautam Kumar *Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Jason W Wang *Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada.
Lara K MahalDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada.ORCID http://orcid.org/0000-0003-4791-8524
Michael W MeanwellDepartment of Chemistry, University of Alberta, Edmonton, Alberta, Canada. meanwell@ualberta.ca.ORCID http://orcid.org/0000-0002-4217-8478

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C4'-modified nucleoside analogs continue to attract global attention for treating infectious diseases and as components in oligonucleotide therapeutics. Current preparations mostly employ lengthy semi-synthetic approaches that do not allow for the efficient exploration of the chemical space associated with this valuable nucleoside subclass. Here we describe the pilot-scale (250 mg) and process-scale (85 g) preparation of 4'-methyl-ribothymidine (4',5-dimethyluridine) using a de novo strategy. Both L- and D-nucleoside analogs are accessible, and 10 different C4' modifications and 20 different nucleobases can be used interchangeably to create new analogs. This protocol involves the use of an enantioselective proline-catalyzed aldol between 2,2-dimethoxyacetaldehyde and a dioxanone. A 1,2-addition into the aldol product installs the C4' modification. Subsequent cyclization via intramolecular trans-acetalization delivers the modified ribose core of the nucleoside analog. Peracetylation, followed by Vorbrüggen glycosylation, completes the route. The pilot- and process-scale protocols can be completed in ~5 and ~7 d, respectively, to deliver C4'-modified nucleoside analogs in good yields and excellent enantiopurity.

Indexed as

NucleosidesThymidineStereoisomerismNucleosidesThymidine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.